Skip to content

Metabolic Cost of Walking With Passive vs. Powered Prosthetic Knees Among Persons With Limb Loss

Metabolic Cost of Walking With Passive vs. Powered Prosthetic Knees Among Persons With Limb Loss

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05831696
Enrollment
12
Registered
2023-04-26
Start date
2023-02-27
Completion date
2026-12-01
Last updated
2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transfemoral Amputation

Keywords

Power Knee, Amputation, Metabolic Costs, Heart Rate

Brief summary

The purpose of this industry-initiated research study is to test that a powered microprocessor controlled knee improves metabolic function during walking in level and sloped conditions as compared to the subject's physician prescribed prosthesis.

Detailed description

The Procedures include: Initial Visit: 1. Informed consent 2. HIPAA authorization 3. Determine/verify ambulation potential 4. Take and record body measurements (height, weight, circumferences) 5. Activities-Specific Balance Confidence (ABC) scale 6. L.A.S.A.R. Posture alignment assessment with RxPx Second Visit 1. Fit with heartrate monitor and metabolic analyzer mask 2. Treadmill Test (level-ground) with RxPx 3. Rest 4. Treadmill Test (incline) with RxPx 5. Fit subject with PMPK 6. L.A.S.A.R. Posture alignment assessment with PMPK 7. Subject uses PMPK for one week as their primary prosthesis Third Visit (1 week later) 1. Fit with heartrate monitor and metabolic analyzer mask 2. Treadmill Test (level-ground) with PMPK 3. Rest 4. Treadmill Test (incline) with PMPK 5. Activities-Specific Balance Confidence (ABC) scale 6. Return PMPK and refit of RxPx 7. Verify alignment with L.A.S.A.R. Posture alignment 8. Check that all fasteners are secure

Interventions

OTHERPowered Microprocessor-controlled Knee (PMPK)

A microprocessor-controlled Knee with standardized commercial prosthetic foot

Sponsors

Loma Linda University
Lead SponsorOTHER
Össur Iceland ehf
CollaboratorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Participants will be their own control

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Males and Females with unilateral knee disarticulation or transfemoral (KD/TF) amputation. * a body mass greater than 49Kg and less than 117Kg * 18-75 years of age * Have an ambulation potential of K3 or K4 * Use a prosthesis daily for walking or sports activities * No less than six months of experience with a prosthesis * No socket issues or changes in the last six weeks * No residual limb pain affecting functional ability.

Exclusion criteria

* Cannot walk at different speeds (MCFL K0-K2) * Limb-loss below the knee or through the hip * More than one amputation. * Uses an assistive device for walking * Uncontrolled edema in leg compartments * Compromised skin of the residual limb or contralateral foot * Are 180 days or less post-amputation * Pregnant (self-reported)

Design outcomes

Primary

MeasureTime frameDescription
VO2 uptake - level groundChange between Baseline Visit (study enrollment) and Visit 2 (3 weeks post-study enrollment)VO2 uptake during ambulation on a treadmill - level ground
VO2 uptake - inclineVisit 2 (3 weeks post-study enrollment)VO2 uptake during ambulation on a treadmill - 5 degree incline

Secondary

MeasureTime frameDescription
Balance confidenceAt Baseline Visit (study enrollment)Activities based balance confidence survey (0-100%) higher score means more balance confidence
ExertionChange between Visit 2 (3 weeks post-study enrollment) and Visit 3 (4 weeks post-study enrollment)Borg Exertion Scale (0-10) with 10 being maximum exertion

Countries

United States

Contacts

CONTACTMichael Davidson, Ph.D.
mdavidson@llu.edu9095586516
PRINCIPAL_INVESTIGATORMichael Davidson, Ph.D.

Loma Linda University Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026